Table 2.

CSF markers before and after treatment. Comparison of difference of biomarkers between baseline and follow up within and between the two treatment groups

	Galantamine			Risperidone
	Baseline M±SD	Follow-up M± SD	P Between group	Baseline M± SD	Follow-up M± SD	P Within group Galantamine	P Within group Risperidone
Total Tau (pg/ml)	731.8±430.39	728.9±414.89	0.96	755.4±460.1	749.7±568.4	0.930	0,878
Aß1-42 (pg/ml)	468.2±205.2	449.1±155.04	0.39	490.8±175.8	450.8±166.2	0,260	0,026
Phosphorylated-Tau (pg/ml)	103.2±63.38	90.8±39.63	0,147	94.9±56.20	89.1±49.92	0,147	0,210
Aß40/42 ratio (pg/ml)	0.52±0.266	0.51±0.210	0.91	0.54±0.240	0.53±0.203	0.425	0.207

Data are presented as means and standard deviations. Independent T-test was used to analyze effects between treatment groups. Depended T-test was used for analysis of within treatment group effects. Significant results considered at p<0.05